SHH and myeloid neoplasm: Of these pathways, SHh signaling is gaining considerable attention as a therapeutic target for myeloid malignancies [40], [41], despite the fact that its role in normal and malignant human hematopoiesis remains poorly defined and controversial [42]–[44].